Sucessful closure of US FDA Inspection at Piramal Pharma''s Manufacturing Facility located at Turbhe.
Awaiting price reaction for this filing.
Piramal Pharma Limited has announced the successful closure of a US FDA inspection at its Turbhe manufacturing facility. The FDA had conducted a General Good Manufacturing Practices (GMP) inspection from February 11 to February 17, 2025. Following this, the FDA issued an Establishment Inspection Report (EIR) classifying the facility as VAI (Voluntary Action Indicated), which means no mandatory corrective actions are required. The EIR receipt formally closes the inspection process for the Turbhe site.
This is positive news for shareholders as the clean VAI classification removes regulatory uncertainty around the Turbhe facility, supports uninterrupted US export operations, and reflects well on the company's manufacturing quality standards.